Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee - 29/05/24

Doi : 10.1016/S1470-2045(24)00094-9

Yi Lin, ProfMD PhD ^a,⁎ , Lugui Qiu, ProfMD ^b, Saad Usmani, ProfMD MBA ^c, Chng Wee Joo, ProfMD ^d, Luciano Costa, ProfMD PhD ^e, Benjamin Derman, MD ^f, Juan Du, ProfMD PhD ^g, Hermann Einsele, ProfMD FRCP ^h, Carlos Fernandez de Larrea, ProfMD PhD ⁱ, Roman Hajek, ProfMD PhD ^j,^k, P Joy Ho, Prof ^l, Efstathios Kastritis, MD ^m,ⁿ, Joaquin Martinez-Lopez ^o, Maria-Victoria Mateos, ProfMD PhD ^p, Joseph Mikhael, ProfMD ^q, Philippe Moreau, ProfMD ^r, Chandramouli Nagarajan, MBBS FRCP ^s, Ajay Nooka, ProfMD MPH ^t, Michael O’Dwyer, ProfMD ^u, Fredrik Schjesvold, ProfMD PhD ^v, Surbhi Sidana, MD ^w, Niels WCJ van de Donk, ProfMD PhD ^x, Katja Weisel, ProfMD ^y, Sonja Zweegman, ProfMD PhD ^x, Noopur Raje, ProfMD ^z, Paula Rodriguez Otero, MD PhD ^aa, Larry D Anderson, ProfMD PhD ^ab,^ac, Shaji Kumar, ProfMD ^a, Tom Martin, Prof ^ad
on behalf of the
International Myeloma Working Group

^a Department of Hematology, Mayo Clinic, Rochester, MN, USA

^b Institution of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

^c Memorial Sloan Kettering Cancer Center, New York, NY, USA

^d Department of Medical Oncology, National University Cancer Institute, Singapore

^e Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

^f Department of Hematology and Oncology, University of Chicago, Chicago, IL, USA

^g Shanghai Changzheng Hospital, Shanghai, China

^h Department of Internal Medicine II, University Hospital, Wurzburg, Germany

ⁱ Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

^j Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic

^k Department of Hematooncology, Faculty of Medicine, University Ostrava, Ostrava, Czech Republic

^l Institute of Hematology, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia

^m Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

ⁿ Alexandra General Hospital, Athens, Greece

^o Hospital Universitario 12 de Octubre, Department of Medicine, Complutense University, CNIO, Madrid, Spain

^p Hospital Universitario de Salamanca, Salamanca, Spain

^q Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA

^r Department of Hematology, University Hospital of Nantes, Nantes, France

^s Department of Haematology, Singapore General Hospital, Singapore

^t Winship Cancer Institute of Emory University, Atlanta, GA, USA

^u Department of Medicine and Department of Haematology, National University of Ireland, Galway, Ireland

^v Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway

^w Department of Hematology, Stanford University, Standford, CA, USA

^x Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands

^y Wilhelminen Cancer Research Institute, First Department of Medicine, Clinic Ottakring, Vienna, Austria

^z Department of Medicine, Harvard University, Cambridge, MA, USA

^aa Department of Hematology, Cancer Center Clinica Universidad de Navarra, Pamplona, Navarra, Spain

^ab Simmons Comprehensive Cancer Center, Dallas, TX, USA

^ac University of Texas Southwestern Medical Center, Dallas, TX, USA

^ad Department of Hematology, University of California, San Francisco, CA, USA

^* Correspondence to: Prof Yi Lin, Department of Hematology, Mayo Clinic, Rochester, MN 55905, USA Department of Hematology Mayo Clinic Rochester MN 55905 USA

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Wednesday 29 May 2024
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Summary

Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.

Le texte complet de cet article est disponible en PDF.